{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T05:28:52Z","timestamp":1731734932425,"version":"3.28.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"DOI":"10.7759\/cureus.73774","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T22:19:38Z","timestamp":1731709178000},"source":"Crossref","is-referenced-by-count":0,"title":["Rheumatic Immune-Related Adverse Events With Anti-cyclic Citrullinated Peptide Positivity and Cutaneous Adverse Drug Reactions: A Case Report"],"prefix":"10.7759","author":[{"given":"Akiko","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang C","year":"2014","unstructured":"Wang C, Thudium KB, Han M, et al.. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014, 2:846-56. 10.1158\/2326-6066.CIR-14-0040","journal-title":"Cancer Immunol Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2169\/naika.112.704","article-title":"[Report from 32nd Tokai Chapter Educational Seminar: advances in immune checkpoint inhibitor that physicians need to know]","volume":"112","author":"Nakamura M","year":"2023","unstructured":"Nakamura M, Yasuda H, Kitano S, et al.. [Report from 32nd Tokai Chapter Educational Seminar: advances in immune checkpoint inhibitor that physicians need to know]. J Jpn Soc Int Med. 2023, 112:704-14. 10.2169\/naika.112.704","journal-title":"J Jpn Soc Int Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine M","year":"2021","unstructured":"Kostine M, Finckh A, Bingham CO, et al.. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021, 80:36-48. 10.1136\/annrheumdis-2020-217139","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine M","year":"2018","unstructured":"Kostine M, Rouxel L, Barnetche T, et al.. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018, 77:393-8. 10.1136\/annrheumdis-2017-212257","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar M","year":"2018","unstructured":"Lidar M, Giat E, Garelick D, et al.. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018, 17:284-9. 10.1016\/j.autrev.2018.01.003","journal-title":"Autoimmun Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4035-0","article-title":"Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment","volume":"37","author":"Inamo J","year":"2018","unstructured":"Inamo J, Kaneko Y, Takeuchi T. Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment. Clin Rheumatol. 2018, 37:1107-10. 10.1007\/s10067-018-4035-0","journal-title":"Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac252","article-title":"Association between rheumatic autoantibodies and immune-related adverse events","volume":"28","author":"Mathias K","year":"2023","unstructured":"Mathias K, Rouhani S, Olson D, Bass AR, Gajewski TF, Reid P. Association between rheumatic autoantibodies and immune-related adverse events. Oncologist. 2023, 28:440-8. 10.1093\/oncolo\/oyac252","journal-title":"Oncologist"},{"key":"ref8","article-title":"[Serious eruption and enanthem associated with immune checkpoint inhibitors and an attempt to develop: the analysis of a multidisciplinary early intervention system to suppress skin toxicity]","volume":"34","author":"Satouchi M","year":"2018","unstructured":"Satouchi M, Takai T, Nakahara T, et al.. [Serious eruption and enanthem associated with immune checkpoint inhibitors and an attempt to develop: the analysis of a multidisciplinary early intervention system to suppress skin toxicity]. J Clin Ther Med. 2018, 34:405-19.","journal-title":"J Clin Ther Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger SM","year":"2016","unstructured":"Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, Dummer R. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016, 22:4023-9. 10.1158\/1078-0432.CCR-15-2872","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler AN","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, et al.. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020, 83:1255-68. 10.1016\/j.jaad.2020.03.132","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/307959-rheumatic-immune-related-adverse-events-with-anti-cyclic-citrullinated-peptide-positivity-and-cutaneous-adverse-drug-reactions-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T22:19:39Z","timestamp":1731709179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/307959-rheumatic-immune-related-adverse-events-with-anti-cyclic-citrullinated-peptide-positivity-and-cutaneous-adverse-drug-reactions-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.73774","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}